First MS Patient Receives ‘Off-the-Shelf’ CAR T-Cell Therapy

Published on: Multiple Sclerosis News Today

A U.S. trial has treated the first multiple sclerosis (MS) patient with azercabtagene zapreleucel, an “off-the-shelf” CAR T-cell therapy made from healthy donor cells. The approach targets CD19 on B-cells to reduce inflammation and nerve damage. This Phase 1 study aims to assess safety and potential to slow disability progression in progressive MS.

👉 Read the full article: First MS Patient Treated With Off-the-Shelf CAR T-Cell Therapy

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.